Mustafa Thaier Al-Karaghouli
@mkaraghouli
Mesopotamian | PGY-3 @UofA | Research passionate 🔬I Master of science in Hepatology I Gl passionate |2024 AASLD ELS 🥇
ID: 1243098684054622208
26-03-2020 08:53:26
28 Tweet
126 Followers
461 Following
First authorship experience Glad to collaborate with Juan G Abraldes, thank you for the supervision, and your invaluable support and feedback. Thank you to everyone who contributed to this project. dx.doi.org/10.1136/bmjgas…
Congrats to DoM's Dr. Mang Ma University of Alberta GI 🌲🇨🇦 for his excellence in teaching and leadership and receiving the UAlberta Med & Dent Dr. Richard Fedorak Memorial Award in Professionalism. Narmin Kassam ualberta.ca/department-of-…
AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review Guadalupe GarciaTsao Juan G Abraldes Nicole Rich Vincent Wong gastrojournal.org/article/S0016-…
In my ALD clinic, I noticed that more than 30% of my patients have >2 components of the metabolic syndrome. Happy that Nature Reviews Gastroenterology & Hepatology devotes its cover to our article on this relevant clinical topic. shorturl.at/yPUZ0 EASL Education #livertwitter #MedTwitter
Patients with #cirrhosis need lots of calories to avoid malnutrition In general we say 35 kcal/kg But! Brooke Chapman shows that many are super hypermetabolic and may need even more doi.org/10.3390/nu1522… #livertwitter Especially high MELD patients with bad ascites
Honored and thrilled to receive the 2024 AASLD Foundation AASLD Emerging Liver Scholar Award Excited for the opportunity to connect and share knowledge with #liver lovers I would like to thank my amazing mentor for the support Juan G Abraldes Next: CaRMS GI fellowship
🌟New Pub: Prophylactic antibiotics in 🍺 patients receiving steroid Liver International Ethan Quek ✅510 pts ✅💊 vs control ✅Less infection, HE ⛔️No benefits in survival (30/90-D) & AKI tinyurl.com/yv7tfmdj #Livertwitter #GiTwitter #MedEd #alcohol
The MELD score at 28 days is a powerful predictor of 90-day survival Could be used as an outcome in clinical trials What do you think? journals.lww.com/hepcomm/fullte… Hepatology Communications
Not everyone drinking excess alcohol will develop liver disease. Great work Fred Ho, Fanny Petermann et al showing additive interaction of diet and alcohol for ArLD, after controlling for MASLD risks. Study of Alcohol-related LiVer disease in Europe Elliot Tapper #livertwitter nature.com/articles/s4146…
Thank goodness!! #gitwitter #livertwitter. Just like Elliot Tapper taught me, when I was green.
Less=More w #antibiotics in #cirrhosis & ✅ reconsider #SecSBPProphylaxis AJG - The American Journal of Gastroenterology⤵️ pubmed.ncbi.nlm.nih.gov/39235290/ 🔑#SecSBPPr vs others▶️⬆️SBP recurrence &🚫mortality benefit 🔑2 datasets (VA Research & TriNetX) w similar trends 🔑worsens over time & validated locally Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟